Loading...
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong, A Halabi, S Eisen, T Broderick, S Stadler, W Jones, R Garcia, J Vaishampayan, U Picus, J Hawkins, Robert E
Armstrong, A
Halabi, S
Eisen, T
Broderick, S
Stadler, W
Jones, R
Garcia, J
Vaishampayan, U
Picus, J
Hawkins, Robert E
Citations
Altmetric:
Abstract
Non-clear cell renal cell carcinomas are histologically and genetically diverse kidney cancers with variable prognoses, and their optimum initial treatment is unknown. We aimed to compare the mTOR inhibitor everolimus and the VEGF receptor inhibitor sunitinib in patients with non-clear cell renal cell carcinoma.
Description
Date
2016-01-12
Publisher
Collections
Keywords
Type
Article
Citation
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. 2016: Lancet Oncol